Fox Run Management, L.L.C. Nektar Therapeutics Transaction History

Fox Run Management, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$4.16 - $13.72 $57,753 - $190,474	-13,883 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$10.83 - $18.41 $150,352 - $255,586	13,883 New	13,883 $188,000
Q1 2020 May 08, 2020	SELL	$14.47 - $27.96 $229,233 - $442,942	-15,842 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $251,412 - $366,267	15,842 New	15,842 $342,000
Q1 2019 Oct 17, 2019	SELL	$31.58 - $46.35 $368,507 - $540,858	-11,669 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$30.43 - $56.65 $355,087 - $661,048	11,669 New	11,669 $384,000
Q3 2018 Oct 05, 2018	SELL	$46.46 - $68.49 $240,569 - $354,641	-5,178 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$46.25 - $104.45 $148,323 - $334,971	3,207 Added 162.71%	5,178 $253,000
Q1 2018 Apr 17, 2018	BUY	$57.4 - $108.44 $113,135 - $213,735	1,971 New	1,971 $209,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.